Congruence Therapeutics picks up $50m in Series A funding

Montreal-based biotechnology startup Congruence Therapeutics has secured $50 million in Series A financing.

8 February 2022•3 mins read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles